- Future health care leaders and innovators will accelerate their path through the McKenna Life Sciences, Business and Entrepreneurship Program, enabling the next generation of biotech game changers.
- A cross-college collaboration between the W. P. Carey School of Business and The College of Liberal Arts and Sciences, the program reflects ASU’s decade-long status as America’s most innovative university.
- The program will launch in 2026 through a generous gift from Mark and Sheri McKenna.
Author Archive: AZBio
Drug discovery startup based on UA research receives $4 million seed funding
The preclinical stage company was founded to commercialize drugs to treat multiple cancers.Continue reading
BIO Announces Dedicated Focus on Human Health and Biopharmaceutical Innovation
- BIO to Transition Agricultural and Environmental Biotech Workstreams
- Key Senior Hires Bolster Focus on Regulatory Affairs, Emerging Companies
and Economic Growth
Study says original COVID-19 vaccination did not stop immune system from fighting variants
- Vaccinated people generated an overall protective immune response to the Delta and Omicron strains of COVID-19, though with slightly fewer antibodies for the mutated parts of the virus.
- University of Arizona Health Sciences researchers found that people who received the original COVID-19 vaccine had greater antibody production against the Delta and Omicron variants than those who were unvaccinated.
- Prior COVID-19 vaccination did not stop the immune system from mounting a protective response to the Delta and Omicron strains, though new mutation-specific antibody production dipped slightly, according to a study led by researchers at the University of Arizona Health Sciences and published in Nature Immunology.
Study reveals weakness in rare ovarian cancer tumors that may lead to improved treatment options
Findings could suggest new targets for immunotherapy
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
Cargill’s Bioindustrial business Partners with Arizona State University to Explore New Materials for Semiconductor Innovation
TEMPE, Ariz. (May 15, 2025) — Cargill Bioindustrial and Arizona State University (ASU) are launching a new, year-long research partnership focused on advanced materials used in semiconductor technology — the foundation of modern electronics from smartphones to electric vehicles.
The research is focused on Cargill™ Priamine™ dimer diamine, which is made from bio-based ingredients. With support from ASU’s Biodesign Institute, scientists will study how and why this material performs so well, and how it might be used to improve the speed, efficiency, and reliability of electronic devices.Continue reading
Navigating CRO and CMO Relationships – AZBioPEERS Video
Selecting and managing the right CRO or CMO partner can make or break an early-stage company’s path to market. Join us for a practical, insight-packed webinar exploring how to evaluate, engage, and grow with outsourcing partners that align with your technical needs, regulatory goals, and growth plans.Continue reading
Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer
- The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment.
- The device uses artificial intelligence-based image analysis with a level of diagnostic precision not possible with traditional manual scoring methods.
- This Breakthrough Device Designation (BDD) demonstrates Roche’s continued innovation in companion diagnostics and digital pathology to enable more precise diagnosis in oncology.
Genetic Factors May Influence Liver Fat Even in Healthy Weight People
TGen Study improves our understanding of steatotic liver disease in an understudied population